Position Reflects Growing Importance of Business Partnerships
CAMBRIDGE, Mass., July 9 /PRNewswire-FirstCall/--
Biogen, Inc. (Nasdaq: BGEN) announced today that Christine Carberry has been
appointed Vice President, Program and Alliance Management. Ms. Carberry will
oversee Biogen's development programs in the areas of autoimmune diseases,
neurodegeneration, oncology and fibrosis. She also will be responsible for
maintaining current and future business partnerships in these areas. She
reports to John Palmer, Senior Vice President, Corporate Development.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Mr. Palmer said, "Biogen is on course to be a multi-product, multi-billion
dollar company, and as the company moves forward, developing partnerships with
businesses on novel therapeutic programs will play an even greater role in
enhancing our already robust product pipeline. Christine brings skill in
managing business alliances and more than 15 years of industry experience to
this new position, and she will be instrumental in creating new opportunities
for the company."
Biogen has increased its emphasis on program development with partner
companies over the last few years, most recently collaborating with Celltech
Group plc on CDP 571, currently in Phase III trials for Crohn's disease.
Biogen is also collaborating with Elan Corporation, plc on ANTEGREN(R)
(natalizumab), which is in Phase III trials for multiple sclerosis and Crohn's
disease, and with ICOS Corporation on LFA-1 (Leukocyte Function-associated
Antigen-1), in Phase II trials for the treatment of immuno-inflammatory
diseases, including psoriasis.
Ms. Carberry joined Biogen in 1984 and held many positions in Technical
Operations, including managing the start-up of Biogen's manufacturing facility
in the Netherlands from 1999 to 2001. She was most recently the Program
Executive of the LFA-1 program, which is developing orally active small
molecule antagonists that work to inhibit T-cell migration and activation that
can lead to inflammatory diseases.
Ms. Carberry holds a Master of Science in Innovation and Technology
Management from Boston University and a Bachelor of Science in Biochemistry
from the University of New Hampshire.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and European sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, (Please see full prescribing information at
http://www.avonex.com.), and from the worldwide sales by licensees of a number
of products, including alpha interferon and hepatitis B vaccines and
diagnostic products. Biogen's research and development activities are focused
on novel products to treat inflammatory and autoimmune diseases, neurological
diseases, cancer, fibrosis and congestive heart failure. The Company
maintains active clinical research programs in protein therapeutics, small
molecules, genomics and gene therapy. For copies of press releases and
additional information about the Company, please consult Biogen's homepage on
the World Wide Web at http://www.biogen.com.
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Amy Brockelman, Manager, Public Affairs,
+1-617-679-3860, or Christina Dillon, Manager, Investor
Relations, +1-617-679-2521, both of Biogen, Inc.
|
